Table 3.
Multivariate analysis of prognostic factors in LA NPC patients.
| Endpoint | Characteristic | HR | 95% CI | P-value |
|---|---|---|---|---|
| OS | With vs. without nimotuzumab | 2.650 | 1.076-6.530 | 0.034 |
| III vs. IV* | 0.287 | 0.116-0.706 | 0.007 | |
| PFS | III vs. IV* | 0.401 | 0.206-0.781 | 0.007 |
| Male vs. female | 2.691 | 1.119-6.472 | 0.027 | |
| With or without comorbidity | 3.022 | 1.068-8.549 | 0.037 | |
| LRRFS | - | - | - | - |
| DMFS | With vs. without nimotuzumab | 4.032 | 1.482-10.968 | 0.006 |
| III vs. IV* | 0.330 | 0.138-0.788 | 0.013 |
OS: Overall Survival. PFS: Progression-Free Survival. LRRFS: Locoregional Recurrence-Free Survival. DMFS: Distant Metastasis-Free Survival.
*The 7th AJCC/UICC staging system.